GILD: Gilead Update
Back on June 7, we suggested investors take a look at Gilead. Gilead is a huge biopharma that is in the race for treatments for Covid-19. This article is for…
Back on June 7, we suggested investors take a look at Gilead. Gilead is a huge biopharma that is in the race for treatments for Covid-19. This article is for…
On 23-June-2020, we presented our opinion concerning the price of long term bonds as represented by TLT, the 20+ year T-Bond ETF. In that discussion, we suggested that bond prices…
Biglots made an exciting announcement on Friday, and that communication caught the investment world flat-footed. This article is for paid members - please login or subscribe for access.
The rails have been one of the surprising beneficiaries since the financial crisis. We say surprisingly because, in the 70, 80 & the 90s, the railroads have been poor financial…
Every day, we talk to the average person on the street, and they cannot understand why the stock market is moving higher while the average person's experience is not so…
As much as the stock market shocks the average bloke, it is the bond market that has people scratching their heads. This article is for paid members - please login…
Peloton is one of the Covid-19 stocks. At first blush, you might think it would be a marginal beneficiary for the lockdown. Since people cannot go out, they decide to…
We have been keeping an eye on Craft Heinz ever since the stock took a beat down due to overpaying for the Kraft Foods business. This article is for paid…
It is not every day we talk about the trucking industry. Trucking is not a sexy industry, but it is quite vital. Further, it provides a good picture of what…
At least that is what the stock market is telling us. Even in the midst of a pandemic, Tesla continues to reach new heights.
Standard monthly options are set to expire this Friday. We have 8 open trade suggestions that have at least 1 leg of the trade structure coming due at the end…
Tesla is one of the companies investors talk about almost every day. The company, product, and its founder have certainly captured the imagination of the investing public. This article is…